Press Releases Year None2020201920182017 October 13, 2020 SpringWorks Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares PDF Version October 7, 2020 SpringWorks Therapeutics Announces Pricing of Public Offering of Common Stock PDF Version October 6, 2020 SpringWorks Therapeutics Announces Proposed Public Offering of Common Stock PDF Version October 5, 2020 SpringWorks Therapeutics Announces Clinical Collaboration with Pfizer Inc. to Evaluate Nirogacestat in Combination with PF‐06863135 in Patients with Relapsed or Refractory Multiple Myeloma PDF Version September 22, 2020 SpringWorks Therapeutics to Participate in H.C. Wainwright Precision Oncology Investor Conference PDF Version September 21, 2020 Precision BioSciences and SpringWorks Therapeutics Announce Clinical Collaboration to Evaluate PBCAR269A in Combination with Nirogacestat in Patients with Relapsed or Refractory Multiple Myeloma PDF Version September 18, 2020 SpringWorks Therapeutics Enters into Sponsored Research Agreement with Fred Hutchinson Cancer Research Center to Further Evaluate Nirogacestat as a BCMA Potentiator in Multiple Myeloma PDF Version September 16, 2020 SpringWorks Therapeutics Announces Collaboration with Children’s Oncology Group to Conduct a Phase 2 Clinical Trial of Nirogacestat in Pediatric Patients with Desmoid Tumors and Reports Publication of Nirogacestat Case Series in Pediatric/Young Adult Desmoid Tumor Patients PDF Version September 14, 2020 SpringWorks Therapeutics Announces Clinical Collaboration with Janssen to Evaluate Nirogacestat in Combination with Teclistamab in Patients with Relapsed or Refractory Multiple Myeloma PDF Version August 12, 2020 SpringWorks Therapeutics Reports Second Quarter 2020 Financial Results and Recent Business Highlights PDF Version Pagination Current page 1 Page 2 Page 3 Page 4 Page 5 Next page next › Last page last »
October 13, 2020 SpringWorks Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares PDF Version
October 7, 2020 SpringWorks Therapeutics Announces Pricing of Public Offering of Common Stock PDF Version
October 6, 2020 SpringWorks Therapeutics Announces Proposed Public Offering of Common Stock PDF Version
October 5, 2020 SpringWorks Therapeutics Announces Clinical Collaboration with Pfizer Inc. to Evaluate Nirogacestat in Combination with PF‐06863135 in Patients with Relapsed or Refractory Multiple Myeloma PDF Version
September 22, 2020 SpringWorks Therapeutics to Participate in H.C. Wainwright Precision Oncology Investor Conference PDF Version
September 21, 2020 Precision BioSciences and SpringWorks Therapeutics Announce Clinical Collaboration to Evaluate PBCAR269A in Combination with Nirogacestat in Patients with Relapsed or Refractory Multiple Myeloma PDF Version
September 18, 2020 SpringWorks Therapeutics Enters into Sponsored Research Agreement with Fred Hutchinson Cancer Research Center to Further Evaluate Nirogacestat as a BCMA Potentiator in Multiple Myeloma PDF Version
September 16, 2020 SpringWorks Therapeutics Announces Collaboration with Children’s Oncology Group to Conduct a Phase 2 Clinical Trial of Nirogacestat in Pediatric Patients with Desmoid Tumors and Reports Publication of Nirogacestat Case Series in Pediatric/Young Adult Desmoid Tumor Patients PDF Version
September 14, 2020 SpringWorks Therapeutics Announces Clinical Collaboration with Janssen to Evaluate Nirogacestat in Combination with Teclistamab in Patients with Relapsed or Refractory Multiple Myeloma PDF Version
August 12, 2020 SpringWorks Therapeutics Reports Second Quarter 2020 Financial Results and Recent Business Highlights PDF Version
